Lyramid SPA & MK Cell License Update

AI SummaryClose X

Roquefort Therapeutics plc has extended the Longstop Dates for both the Lyramid SPA and the MK Cell Out-License agreements with Pleiades Pharma Ltd to December 31, 2026. This extension is necessary to allow Pleiades sufficient time to complete its ongoing fundraising round with GCC investors, as completion of both the Lyramid subsidiary sale and the MK Cell patent out-licensing are contingent on this fundraising. All other terms of the existing agreements remain unchanged.

Disclaimer*

UK 100

Latest directors dealings